UNIVERSITY OF EDINBURGH
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 1583-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.ed.ac.uk
Novel Non-Hormonal Male Contraceptive "Adam" Shows Two-Year Efficacy in Clinical Trials
A new non-hormonal male contraceptive implant called Adam has demonstrated effectiveness for at least two years in initial clinical trials, with no sperm detected in participants reaching the 24-month mark.
Antidepressants Linked to Increased Risk of Sudden Cardiac Death, Danish Study Reveals
New research from Denmark shows antidepressant use is associated with an increased risk of sudden cardiac death, with risk rising based on duration of exposure.
AI Advances in Breast Cancer Detection: New Technologies Show Promise for Earlier Diagnosis
AI technology developed at Washington University can analyze sequential mammograms to identify subtle tissue changes, predicting breast cancer risk 2.3 times more accurately than standard methods.
Breakthrough: Combined Drug Therapy Shows Near-Complete Elimination of Liver Cancer in Study
Scottish researchers discover that combining cladribine with lenvatinib nearly eradicates hepatocellular carcinoma tumors in groundbreaking preclinical study led by Professor Tom Bird.
Early Aortic Valve Intervention Fails to Show Benefit in Asymptomatic Patients with Severe Aortic Stenosis and Myocardial Fibrosis
A randomized clinical trial involving 224 patients revealed that early aortic valve intervention did not significantly reduce the composite outcome of all-cause death or unplanned aortic stenosis-related hospitalization.
EVOLVED Trial: Early Aortic Valve Replacement Fails to Show Mortality Benefit in Asymptomatic Patients with Fibrosis
The EVOLVED study found that early aortic valve replacement (AVR) in asymptomatic patients with myocardial fibrosis did not reduce all-cause mortality or unplanned aortic stenosis-related hospitalizations.
SGLT-2 Inhibitors Linked to Reduced Dementia Risk in Type 2 Diabetes Study
A new study suggests that Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, used for treating type 2 diabetes, are associated with a lower risk of developing dementia.